Trial reportInternational urology and nephrology2025
Low-intensity extracorporeal shockwave therapy in patients with diabetic kidney disease: a matched cohort study.
Trial report in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02515461 (Low Energy Shockwave Therapy), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Low Energy Shockwave Therapy (LE-SWT): A Novel Treatment for Chronic Kidney Disease
Who cites it
1 citing paper in PubMed.
- Feasibility and safety of electrohydraulic acoustic therapy for treatment of hypertension in patients with chronic kidney disease.Frontiers in medical technology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLow-intensity extracorporeal shockwave therapy (LI-ESWT) is a potential novel treatment against diabetic kidney disease (DKD). The present study investigates the longer term effects of LI-ESWT on kidney function in patients with DKD.
methodsThis matched cohort study included 28 patients with DKD, who received six sessions of LI-ESWT. Patients were matched 1:5 with patients from the Funen Diabetes Database. Multivariable adjusted eGFR and ACR were analyzed using multilevel mixed-effects linear regression. The primary outcomes were ACR and eGFR measured at 3, 6, 12, and 18 month follow-up. Secondary analyses with patients stratified for sex, age, baseline eGFR, and baseline ACR were made for the multivariable adjusted values of eGFR and ACR.
resultsNo significant difference in multivariable adjusted ACR or eGFR was found at 18 months. The intervention group showed a non-significant decrease in adjusted eGFR (1.83 mL/min/1.73 m
conclusionLI-ESWT did not demonstrate overall statistically significant effects on eGFR and ACR at 3, 6, 12, or 18 months. However, secondary analyses suggest possible effects in certain subgroups. Clinical studies with larger samples are needed to clarify the efficacy of LI-ESWT in specific DKD patient subgroups. Trial Registration The trial was prospectively registered July 31, 2015, at ClinicalTrials.gov with registration number NCT02515461.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.